An immunoglobulin agent (IVIG) inhibits NF-κB activation in cultured endothelial cells of coronary arteries in vitro

Inflammation Research

Volumn 53, Issue 6, 2004, Pages 253-256

  Ichiyama, T ^a   Ueno, Y ^a   Isumi, H ^a   Niimi, A ^b   Matsubara, T ^a   Furukawa, S ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b BAYER YAKUHIN LTD   (Japan)

Author keywords

Coronary artery endothelial cells; E Selectin; Interleukin 6; Intravenous immunoglobulin; NF B

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CORONARY ARTERY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOGENESIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

ARTERIES; BLOTTING, WESTERN; CELL NUCLEUS; CELLS, CULTURED; CORONARY VESSELS; CYTOKINES; CYTOPLASM; E-SELECTIN; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; I-KAPPA B PROTEINS; IMMUNOGLOBULINS, INTRAVENOUS; INTERLEUKIN-6; NF-KAPPA B; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2142739716     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-004-1255-3     Document Type: Article

References (23)

1. Kawasaki T, Kosaki F, Ogawa S, Shigemitsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974; 54: 271-6.
2. Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki disease. Pediatrics 1978; 61: 100-7.
3. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996; 94: 1379-85.
4. Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, Sasai K, et al. Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol 1988; 48: 247-51.
5. Maury CP, Salo E, Pelkonen P. Circulating interleukin-1β in patients with Kawasaki disease. N Engl J Med 1988; 319: 1670-1.
6. Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor a among patients with Kawasaki disease. J Pediatr 1992; 121: 924-6.
7. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; 2: 1055-8.
8. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341-7.
9. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633-9.
10. Leung DY, Burns JC, Newburger JW, Geha RS. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 1987; 79: 468-72.
11. Furukawa S, Matsubara T, Jujoh K, Sasai K, Nakachi S, Sugawara T, et al. Reduction of peripheral blood macrophages/monocytes in Kawasaki disease by intravenous gammaglobulin. Eur J Pediatr 1990; 150: 43-7.
12. Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-83.
13. Ichiyama T, Nishikawa M, Yoshitomi T, Hasegawa S, Matsubara T, Hayashi T, et al. Clarithromycin inhibits NF-κB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 2001; 45: 44-7.
14. Andersson JP, Andersson UG. Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 1990; 71: 372-6.
15. Toungouz M, Denys CH, De Groote D, Dupont E. In vitro inhibition of tumour necrosis factor-α and interleukin-6 production by intravenous immunoglobulins. Br J Haematol 1995; 89: 698-703.
16. Andersson J, Skansén-Saphir U, Sparrelid E, Andersson U. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 1996; 104 (Suppl. 1): 10-20.
17. Ichiyama T, Yoshitomi T, Nishikawa M, Fujiwara M, Matsubara T, Hayashi T, et al. NF-κB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease. Clin Immunol 2001; 99: 373-7.
18. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-36.
19. Boehme MW, Schmitt WH, Youinou P, Stremmel WR, Gross WL. Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides. Am J Med 1996; 101: 387-94.
20. Zakeri SM, Meyer H, Meinhardt G, Reinisch W, Schrattbauer K, Knoefler M, et al. Effects of trovafloxacin on the IL-1-dependent activation of E-selectin in human endothelial cells in vitro. Immunopharmacology 2000; 48: 27-34.
21. Furukawa S, Matsubara T, Yone K, Hirano Y, Okumura K, Yabuta K. Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumour necrosis factor-α and interleukin 6 in serum. Eur J Pediatr 1992; 151: 44-7.
22. Kim DS, Lee KY. Serum soluble E-selectin levels in Kawasaki disease. Scand J Rheumatol 1994; 23: 283-6.
23. Schiller B, Elinder G. Inflammatory parameters and soluble cell adhesion molecules in Swedish children with Kawasaki disease: relationship to cardiac lesions and intravenous immunoglobulin treatment. Acta Paediatr 1999; 88: 844-8.